Astellas Pharma Inc. (FRA:YPH)

Market Cap	19.81B
Revenue (ttm)	11.56B
Net Income (ttm)	719.16M
Shares Out	n/a
EPS (ttm)	0.40
PE Ratio	27.55
Forward PE	n/a
Dividend	0.45 (4.07%)
Ex-Dividend Date	Sep 29, 2025

Volume	100
Average Volume	718
Open	10.88
Previous Close	10.71
Day's Range	10.76 - 11.13
52-Week Range	7.53 - 11.13
Beta	n/a
RSI	71.06
Earnings Date	Feb 3, 2026

About Astellas Pharma

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia (AML); VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD); EVRENZO, a treatment for anemi...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 13,643
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YPH

Financial Performance

In 2024, Astellas Pharma's revenue was 1.91 trillion, an increase of 19.25% compared to the previous year's 1.60 trillion. Earnings were 50.75 billion, an increase of 197.72%.

Financial numbers in JPY